Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 1997

View Archived Issues

Isis Pharmaceuticals: HY 1997 highlights

The Immune Response Corporation: HY 1997 highlights

Aurora Biosciences licenses fluorescent technology from the University of California

NIH researcher outlines ups and downs of malaria vaccine research

CombiChem/Athena initiate CNS drug discovery collaboration

Ginkgo biloba extract stabilizes dementia in patients in U.S. trial

CoCensys receives NIH grant to develop caspase inhibitors

Further indications of divalproex efficacy in dementia

Yale-Vion developing bacteria-based cancer treatment

New formulation of diazepam launched in U.S.

First launch for Yamanouchi bisphosphonate

Megestrol + ibuprofen for cancer cachexia

Potential new anticancer vaccines described

Dexanabinol: pharmacokinetics in humans

P&G agrees to outlicense antiarrhythmic drug

CPC-111 reduces pain of sickle cell crises in phase II

Selective suppression of Th1 cytokine production with TAK-603

RTP Pharma and Elan create company dedicated to ciclosporin development

Pharmacyclics enters into licensing agreement with Nycomed for Lu-Tex

First new narcolepsy therapy in decades cleared in U.K.

Celgene reports phase I/II trial results of d-methylphenidate for ADHD

Novartis granted option for TP-10 in xeno/allotransplants; preliminary results in lung transplant

Positive results obtained with Theratechnologies' AIDS gene therapy

Gensia receives FDA approval for desmopressin acetate injection

Bexxar compared to unlabeled MAb in patients with non-Hodgkin's lymphoma

Update on development of NeoPharm's novel chimeric human protein

Matritech files for clearance of new colon cancer test with FDA

Atlantic's sulfated cyclodextrins effective in preclinical models of restenosis

Taisho, Abbott to collaborate on macrolide antibacterials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...